Jane Street Group LLC Purchases 166,589 Shares of Delcath Systems, Inc. (NASDAQ:DCTH)

Jane Street Group LLC grew its stake in shares of Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) by 1,364.6% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 178,797 shares of the company's stock after purchasing an additional 166,589 shares during the period. Jane Street Group LLC owned about 0.56% of Delcath Systems worth $2,153,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in DCTH. Vivo Capital LLC increased its holdings in Delcath Systems by 71.4% during the 4th quarter. Vivo Capital LLC now owns 1,708,579 shares of the company's stock worth $20,571,000 after purchasing an additional 711,574 shares in the last quarter. Gilder Gagnon Howe & Co. LLC bought a new stake in Delcath Systems during the 4th quarter worth approximately $7,371,000. Silverarc Capital Management LLC bought a new stake in Delcath Systems during the 4th quarter worth approximately $1,870,000. Kennedy Capital Management LLC increased its holdings in Delcath Systems by 89.6% during the 4th quarter. Kennedy Capital Management LLC now owns 258,782 shares of the company's stock worth $3,116,000 after purchasing an additional 122,318 shares in the last quarter. Finally, ADAR1 Capital Management LLC increased its holdings in Delcath Systems by 381.1% during the 4th quarter. ADAR1 Capital Management LLC now owns 149,385 shares of the company's stock worth $1,799,000 after purchasing an additional 118,333 shares in the last quarter. 61.12% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright boosted their price objective on Delcath Systems from $22.00 to $24.00 and gave the stock a "buy" rating in a report on Friday, March 7th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $22.75.

Delcath Systems Trading Down 6.3%

Shares of DCTH stock traded down $1.09 during trading on Thursday, hitting $16.15. The company's stock had a trading volume of 848,552 shares, compared to its average volume of 369,624. The company has a market cap of $562.44 million, a PE ratio of -11.96 and a beta of 0.72. The business has a fifty day moving average of $13.00 and a 200-day moving average of $12.93. Delcath Systems, Inc. has a 52 week low of $6.33 and a 52 week high of $18.23.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.07). Delcath Systems had a negative net margin of 150.70% and a negative return on equity of 338.16%. The firm had revenue of $19.80 million for the quarter, compared to the consensus estimate of $16.83 million. As a group, research analysts predict that Delcath Systems, Inc. will post -0.79 EPS for the current year.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.